How to Be Ready When Blockchain ‘Collides’ with Biotech

Ryan Dinse again.

On my request, I’ve been given permission to sort of ‘take over’ this e-letter until early next week.

Sorry. You’re stuck with me.

But if you choose to keep sticking with me, I think you’ll find what we unwrap over the next few days to be potentially rewarding.

If you’ve been paying attention the last few days, you’ll know we’re taking a step away from the daily hubbub of bubbles, stock markets, Trump and financial chaos.

And instead, we’re looking more closely at a powerful, sweeping, world-changing new disruptive trend.

Few people anywhere in the world — that I know at least — are even aware of this trend. Let alone are they unwrapping it, studying it, seeing where it might go next…and in turn notice the stocks that could become superstars from it.

But that’s precisely what we’re going to be doing.

We will be breaking new ground here.

And yet, while this trend is brand new, there is a precedent.

We talked about the precursor on Monday: the Human Genome Project.

What we’re going to be delving into now is what happens next in genomics.

And understanding this could potentially be extremely valuable to you, if you’re a speculative investor wanting to make exponential gains between now and 2025.

To recap what we’ve covered so far, the human genome sequence is contained in our DNA.

It’s made up of long chains of ‘base pairs’ that form our 23 chromosomes. These sequences then form our 30,000 genes.

We humans have hugely similar genome sequences to each other, but it’s how they’re ordered that makes each of us unique.

In 1990, the American government started a ‘Grand Project’ to determine the sequence, or order, of the human genome.

It eventually cost US$3.8 billion to execute.

The idea was that if you can sequence the genome, you could basically reinvent medicine on a genetic level.

The project was completed in 2003, and in the 15 years since then it has indeed revolutionised medicine.

It has resulted in tailored treatments with fewer side effects.

It has invented personalised care out of nowhere. Doctors can now tailor your treatment to who you are, not just where you fall statistically.

It has produced better clinical studies and advanced our scientific knowledge.

It has also produced better data, aiding doctors in making smarter decisions.

But the Human Genome Project also spawned something else…

A series of ‘spin-off’ investment gains rarely seen in the history of the stock market

From the early 2000s onwards, other biotech companies took what the Human Genome Project was doing and ran with it.

A ‘poster child’ for the new age of genomic medicine is a company call Illumina.

Illumina was a trailblazer in taking whole-genome sequencing and applying it practically and commercially.

If you had owned Illumina shares in the early days when everything was still murky — when no-one really grasped the importance of genetic information in treating inherited disorders and the mutations that drive serious illnesses — right now you’d be sitting on…

…wait for it…

…a share price gain of over 28,000%.



Illumina was not alone…

There were hordes of biotech companies that went commercial off the back of the Human Genome Project.

Many failed.

But some went on to harness the genomic leap forward, improve medicine, make boatloads of money, and in turn make their early investors mind-bogglingly rich.

I mentioned some of these gains on Monday:

  • Celgene went from 51 cents to $142
  • NeoGenomics went from 20 cents to $11.24
  • BioMarin Pharmaceutical Inc. went from $4 to $146
  • Regeneron went from $7 to $548
  • Shire PLC went from $15 to $266
  • Mesoblast went from $7.75 to $50
  • Biogen Inc went from $28 to $409
  • AveXis, Inc went from $17 to $217
  • BeiGene went from $24 to $192
  • Sangamo Therapeutics went from 50 cents to $25
  • Bluebird Bio went from $19 to $231
  • Agilent Technologies went from $9 to $63
  • Celladon went from $4 to $59

I’m reaching out to you this week because there is a NEW genomic project I’d like to introduce you to. And, if I’m right, it could spawn a new set of spin-off gains that could DWARF the ones I mentioned above.

I’ll explain further…


When blockchain met biotech…

When you think of biotech you tend to think of scientists in white lab coats.

You think cloning, genetics and DNA fingerprinting.

But biotech has been a fixture of human society for thousands of years. Of course, we didn’t call it biotechnology for a long time. Not until Hungarian agricultural economist Károly Ereky coined the term in 1919.

Ereky used the word to describe the process of humans using living organisms to transform one thing into something else.

A more useful or desirable product.

And unlike today’s armchair economists, Ereky backed up his theories by having the biggest, most profitable pig farm in Europe at the time.

Fermentation is perhaps the most ancient biotech discovery. Yes, it turns out early man was as keen on a stubby as much as the rest of us modern sapiens.

In fact, we’ve been making beer, wine, vinegar and bread using microorganisms like yeast for over 10,000 years.

Biotech techniques have been improving our lives for a long time.

We’ve been preserving foods using methods of drying, freezing and salting long before anyone even understood what caused food to spoil in the first place.

Even before the 20th Century, biotech was playing a role in the Industrial Revolution. In 1897, we discovered industrial fermentation which led to the production of chemicals such as butanol, acetone, and glycerol.

In the mid-1860s, Gregor Mendel’s studies on inheritable traits of peas improved our understanding of genetic inheritance. This lead to the practice of cross-breeding (now known as hybridisation).

But it was in the 20th Century when the biotech industry really exploded.


The era of DNA and genetics had begun…

As I’ve already mentioned, DNA are the building blocks of life.

So, the understanding and manipulation at this cellular level already has — and will continue to have — some unbelievable and possibly scary results in the future.

Ultra-long life spans, the eradication of disease, designer babies and new human senses could all become a reality in the future.

It’s exciting, but controversial stuff.

We saw the final stage of the Human Genome Project in 2003.

This major achievement has already seen great breakthroughs and STUNNING stock gains for those who picked the pioneers early…

But biotech has long been a risky spot for investors.

Years of costly research, combative peer reviews, long hours of experimentation, all in the hope that a crucial breakthrough might occur.

And even if it does, that’s just the beginning.

You then have to try to get your discovery commercialised, and deal with unscrupulous patent trolls (who try to steal your glory) and government regulators (who can make or break your decades of research at the stroke of a pen).

Make no mistake, your entire capital is well and truly at risk here.

But, if you’re keen to accept that risk, then I need you to read what I’m going to show you over the next few days very carefully.

If my research is correct, a new great genomic project is beginning.

In many ways, it’s going to finish what the Human Genome Project started.

And it could send a new breed of tiny biotech companies — listed on both the ASX and US-based NASDAQ indexes — to the moon.

More importantly, this new project will be powered by something called blockchain.

More on blockchain, and its place in the second great genomic revolution of the 21st Century, tomorrow…



Ryan Dinse,
Editor, Exponential Stock Investor

Ryan Dinse is an Editor at Money Morning.

He has worked in finance and investing for the past two decades as a financial planner, senior credit analyst, equity trader and fintech entrepreneur.

With an academic background in economics, he believes that the key to making good investments is investing appropriately at each stage of the economic cycle.

Different market conditions provide different opportunities. Ryan combines fundamental, technical and economic analysis with the goal of making sure you are in the right investments at the right time.

Ryan's premium publications include:

Leave a Reply

Your email address will not be published. Required fields are marked *

Money Morning Australia